Application of miR-378a-5p in promoting differentiation of initialized CD4 + T cells towards Th1 direction
MiR-378a-5p regulates BRAF, promotes the differentiation of CD4+ T cells in Th1 direction, solves the problem of regulation of CD4+ T cell differentiation direction in echinococcosis, improves the immune response, and provides prevention and control of echinococcosis and New ideas for treatment.
Patent Information
- Application Number
- CN202410868909.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-01
- Publication Date
- 2024-12-06
AI Technical Summary
The prior art is difficult to effectively regulate the differentiation direction of CD4+ T cells, especially in echinococcosis, which affects the host's immune response and pathogen clearance ability.
Through research, it was found that miR-378a-5p can regulate its target gene BRAF, promote the initial differentiation of CD4+ T cells in the direction of Th1, inhibit its differentiation in the direction of Th2, thereby enhancing the host's immune response.
The role of miR-378a-5p in the initialization of CD4+ T cells in the mouse spleen was first confirmed, providing new clues and theoretical basis for the prevention and treatment of echinococcosis, and improving the immune protection of hydatis.
Smart Images

Figure CN119082017A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and more particularly to the role of miR-378a-5p in promoting the initialization of CD4 + Application in the differentiation of T cells into Th1 direction. Background Art
[0002] Echinococcosis, also known as echinococcosis, is a zoonotic parasitic disease caused by the larvae of the tapeworm Echinococcus parasitizing the host. It mainly occurs in countries and regions with developed animal husbandry. When the hydatid larvae infect the host, the host will produce a very complex immune response, including humoral immunity, cellular immunity and complement-mediated immune response. Among them, CD4 + T cells play an important role in the relationship between echinococcosis and the host. In the research of early prevention, the research of genetic engineering vaccine has attracted much attention.
[0003] The discovery of non-coding RNA (ncRNA) has had a significant impact on the study of gene expression regulation. Although they lack protein coding ability, they can regulate gene expression and protein function and participate in various biological mechanisms, including growth, migration, autophagy, apoptosis and differentiation. Among them, microRNA is a class of single-stranded non-coding small RNA molecules with a length of about 22 nucleotides that are widely expressed in cells. They mainly degrade target mRNA or inhibit its translation through specific interactions with the 3' untranslated region of their target genes, thereby blocking the formation of target proteins and exerting their regulatory effects. In recent years, more and more studies have revealed that miRNA is involved in the development of a variety of diseases, including different types of cancer, heart disease (such as hypertrophy and ischemia), and diseases associated with mental disorders (such as schizophrenia or major depression). Studies have found that parasitic infections can also cause changes in host miRNAs, thereby regulating the expression of a series of host genes, thereby evading host immune defense. Summary of the invention
[0004] In view of the above technical problems, the present invention provides miR-378a-5p in promoting the initialization of CD4 + The present invention has found that miR-378a-5p can regulate its target gene BRAF and thus affect the initialization of CD4 + The differentiation of T cells provides new clues and theoretical basis for the prevention and treatment of echinococcosis.
[0005] In order to achieve the above-mentioned object of the invention, the present invention adopts the following technical solutions:
[0006] The first aspect of the present invention provides miR-378a-5p in promoting the initialization of CD4 +Application in the differentiation of T cells into Th1 direction.
[0007] The present invention has found through research that the anti-hydatid immune protection of Echinococcus granulosus recombinant protein P29 (rEg.P29) for mice and sheep is 96.6% and 94.5% respectively. rEg.P29 can stimulate the body to produce humoral immunity and cellular immunity at the same time. rEg.P29 immunization can induce high levels of anti-rEg.P29 specific antibodies. The antibody response reaches a peak in the second week after booster immunization and lasts for more than 16 weeks. At the same time, rEg.P29 can promote the initial CD4 + T cells differentiate in the direction of Th1 and produce a large amount of cytokines such as IFN-γ to eliminate pathogens. The present invention uses rEg.P29 as the entry point to construct a mouse hydatid infection model and an rEg.P29 immune model, and uses the second-generation sequencing technology to screen out the microRNA molecules that are differentially expressed in the immune cells of mice before and after rEg.P29 immunization and before and after hydatid infection. The sequencing results showed that compared with the hydatid positive infection group, the rEg.P29 immune group with higher protection had a significantly increased expression level of mmu-miR-378a-5p. The present invention uses the target gene prediction website to predict the target genes that may be regulated by miR-378a-5p, and the dual luciferase reporter gene confirms that its target gene is BRAF. It was verified by qRT-PCR, Western blot and flow cytometry experiments that miR-378a-5p affects the initialization of CD4 by regulating BRAF. + We further determined that miR-378a-5p could promote the initialization of CD4 T cells in the spleen of mice. + It can stimulate T cells to differentiate into Th1 and inhibit their differentiation into Th2.
[0008] In order to verify the effect of miR-378a-5p target gene BRAF on initialization of CD4 + The present invention also synthesized a small interference fragment siRNA-BRAF-1341 of the target gene BRAF, which was used to initialize CD4 + After transfection of the interference fragment into T cells, the results of qRT-PCR, Western blot and flow cytometry showed that the expression of Th1 cytokine IFN-γ increased significantly, while the expression of Th2 cytokine IL-4 decreased significantly. However, the opposite result was obtained after transfection of BRAF overexpression lentivirus, indicating that BRAF inhibited the initial CD4 + T cells differentiate into Th1 and promote their differentiation into Th2.
[0009] In order to verify the functional restoration of the miR-378a-5p target gene BRAF, the present invention initialized CD4 +After co-transfection of miR-378a-5p and BRAF in T cells, the expression of Th1 cytokine IFN-γ and Th2 cytokine IL-4 was detected by qRT-PCR and flow cytometry. + T cell differentiation towards Th1 can be restored by BRAF.
[0010] Since the experiment was designed to be conducted on spleen cells, human experiments could not be conducted, so this experiment was verified in mouse spleen cells. The mature sequence of miR-378a-5p is consistent in mice and humans, so the present invention provides new ideas and directions for clinical exploration of changes in the immune mechanism of patients with echinococcosis infection, and provides new clues and theoretical basis for the diagnosis and prevention of echinococcosis.
[0011] In combination with the first aspect, the nucleotide sequence of the miR-378a-5p is CUCCUGACUCCAGGUCCUGUGU (as shown in SEQ ID No: 1).
[0012] The second aspect of the present invention provides the use of miR-378a-5p mimics in the preparation of hydatid disease prevention or treatment drugs. Since miR-378a-5p mimics can increase the expression of miR-378a-5p in cells, and miR-378a-5p can promote the initialization of CD4 + T cells differentiate in the direction of Th1 and activate cellular immune response, thereby controlling the early formation, growth, metastasis and anti-infection of echinococcosis. Therefore, miR-378a-5p mimics can be used for the preparation of drugs for the prevention or treatment of echinococcosis.
[0013] In conjunction with the second aspect, the miR-378a-5p mimic is double-stranded:
[0014] The sequence of the positive strand is: CUCCUGACUCCAGGUCCUGUGU (as shown in SEQ ID No: 2);
[0015] The sequence of the antisense strand is: ACAGGACCUGGAGUCAGGAGUU (as shown in SEQ ID No: 3).
[0016] The third aspect of the present invention provides a drug for preventing echinococcosis, wherein the active ingredient of the drug includes a miR-378a-5p mimic.
[0017] In conjunction with the third aspect, the miR-378a-5p mimic is double-stranded:
[0018] The sequence of the sense strand is: CUCCUGACUCCAGGUCCUGUGU;
[0019] The sequence of the antisense strand is: ACAGGACCUGGAGUCAGGAGUU.
[0020] In combination with the third aspect, the dosage form of the drug is an injection.
[0021] The third aspect of the present invention provides a drug for treating echinococcosis, wherein the active ingredient of the drug includes a miR-378a-5p mimic.
[0022] In conjunction with the fourth aspect, the miR-378a-5p mimic is double-stranded:
[0023] The sequence of the sense strand is: CUCCUGACUCCAGGUCCUGUGU;
[0024] The sequence of the antisense strand is: ACAGGACCUGGAGUCAGGAGUU.
[0025] In combination with the fourth aspect, the dosage form of the drug is an injection.
[0026] The beneficial effects of the present invention are: initializing CD4 + The differentiation of T cells plays a great role in the host's defense against foreign pathogens and is of great significance for the prevention and treatment of echinococcosis. + The role of miR-378a-5p in T cell differentiation and the targeting relationship between miR-378a-5p and BRAF were also demonstrated through rescue experiments, and the target gene BRAF can restore the cell differentiation caused by miR-378a-5p, thus proving that miR-378a-5p plays a role in initializing CD4 T cell differentiation in mouse spleen. + The invention provides new clues and theoretical basis for the prevention and treatment of echinococcosis. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 The effects of different concentrations of miR-378a-5p mimics and miR-378a-5p inhibitor on the expression level of miR-378a-5p measured by qRT-PCR technology in Example 1 of the present invention;
[0028] Figure 2 The initialization CD4 in the spleen of mice after transfection with miR-378a-5pmimics and miR-378a-5p inhibitor was measured by qRT-PCR technology in Example 1 of the present invention. + Differentiation of T cells;
[0029] Figure 3The interference effects of different interference fragments siRNA-BRAF-972, siRNA-BRAF-1341, siRNA-BRAF-1845 / siRNA-NC and OE-BRAF measured by qRT-PCR technology in Example 1 of the present invention;
[0030] Figure 4 The initialization CD4 in the spleen of mice after transfection with OE-BRAF and siRNA-BRAF-1341 was measured by qRT-PCR technology in Example 1 of the present invention. + Differentiation of T cells;
[0031] Figure 5 is the initialization CD4 measured by qRT-PCR technology in Example 1 of the present invention + Expression of Th1 cytokine IFN-γ and Th2 cytokine IL-4 in T cells after co-transfection of miR-378a-5p and BRAF;
[0032] Figure 6 The initialization CD4 in the spleen of mice after transfection with miR-378a-5p mimics and miR-378a-5p inhibitor measured by Western blot in Example 1 of the present invention + Differentiation of T cells;
[0033] Figure 7 The initialization CD4 in the spleen of mice after transfection with OE-BRAF and siRNA-BRAF-1341 was measured by Western blot in Example 1 of the present invention. + Differentiation of T cells;
[0034] Figure 8 The initial CD4 in the spleen of mice after transfection with miR-378a-5p mimics and miR-378a-5p inhibitor measured by flow cytometry in Example 1 of the present invention + Differentiation of T cells;
[0035] Fig. 9 The initial CD4 in the spleen of mice after transfection with OE-BRAF and siRNA-BRAF-1341 measured by flow cytometry in Example 1 of the present invention + Differentiation of T cells;
[0036] Fig.10 is the initialization CD4 measured by flow cytometry in Example 1 of the present invention +Expression of Th1 cytokine IFN-γ and Th2 cytokine IL-4 in T cells after co-transfection of miR-378a-5p and BRAF;
[0037] Fig.11 is the dual fluorescein reporting result in Example 2 of the present invention;
[0038] Fig.12 This is the animal experiment result of Example 3 of the present invention. DETAILED DESCRIPTION
[0039] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work fall within the scope of protection of the present invention.
[0040] In the present invention, miR-378a-5p mimics represents a mimic of miR-378a-5p, which simulates miR-378a-5p in vivo, is synthesized by chemical synthesis method, and can enhance the expression of miR-378a-5p. NC (negative control) of miR-378a-5p mimics represents a negative control of miR-378a-5p mimics, that is, a sequence similar to the structure of miR-378a-5p mimics but meaningless, which will not overexpress miR-378a-5p. The corresponding NC is transfected in the transfection of miR-378a-5p mimics, the purpose of which is to exclude the influence of transfection of such sequence on the experimental results.
[0041] The miR-378a-5p mimics used in the present invention are double-stranded:
[0042] The sequence of the sense strand is: CUCCUGACUCCAGGUCCUGUGU;
[0043] The sequence of the antisense strand is: ACAGGACCUGGAGUCAGGAGUU.
[0044] In the present invention, miR-378a-5p inhibitor represents an inhibitor of miR-378a-5p, which is a chemically modified inhibitor specifically targeting specific miR-378a-5p in cells. NC of miR-378a-5 inhibitor represents a negative control of miR-378a-5p inhibitor, that is, a sequence similar to the structure of miR-378a-5 inhibitor but meaningless, which does not affect the expression of miR-378a-5p.
[0045] The miR-378a-5p inhibitor used in the present invention is a single chain: ACACAGGACCUGGAGUCAGGAG.
[0046] In the present invention, the NC of miR-378a-5p is an artificially designed double-stranded miRNA molecule that does not target any known human, mouse, and rat genes.
[0047] In the present invention, siRNA-NC is a common negative control having no homology to the sequence of the target gene and no homology to other genes in the target cell.
[0048] The above-mentioned mimetics, inhibitors or NCs, unless otherwise specified, can be designed and obtained by those skilled in the art according to common knowledge.
[0049] The present invention is further explained below in conjunction with specific embodiments.
[0050] Example 1
[0051] This example uses mouse spleen to initialize CD4 + T cells validated the role of miR-378a-5p in priming CD4 + The role of T cell differentiation and the targeting relationship between miR-378a-5p and the target gene BRAF.
[0052] 1. Mouse spleen initialization CD4 + Isolation and culture of T cells:
[0053] (1) Spleen grinding: Kill mice and remove spleen aseptically. Place spleen on a 70 μm filter and gently grind while adding sample diluent to make 5 ml of cell suspension. Mix by pipetting.
[0054] (2) Separation: Add 5 ml of mouse spleen lymphocyte separation solution to a 15 ml centrifuge tube, then tilt the centrifuge tube and slowly add the cell suspension from the previous step twice, centrifuge at 450 x g, 22°C for 20 min;
[0055] (3) Washing: After centrifugation, the tube is divided into four layers. Discard the upper layer of liquid and carefully pipette the buffy coat layer into another clean centrifuge tube. Add 10 ml of washing solution and centrifuge at 350 x g, 22°C for 10 min. Wash twice.
[0056] (4) Counting: Finally, resuspend in complete medium and count;
[0057] (5) After resuspending and counting, the 7 Add 40 μL magnetic bead sorting buffer and 10 μL CD4 + TCell Biotin-Antibody Cocktail, incubate at 4°C in the dark for 5 min;
[0058] (6) According to the calculation of every 1×10 7 Add 20 μL magnetic bead sorting buffer, 20 μL Anti-biotin MicroBeads, and 10 μL CD44 MicroBeads to the cells and incubate at 4°C in the dark for 10 min;
[0059] (7) Fix the sorting column and prepare for sorting. This process is performed on ice. Dilute the incubated cell suspension, wet the sorting column first, then add a certain amount of magnetic bead sorting buffer, add the cell suspension several times, and collect it in a 15 ml centrifuge tube;
[0060] (8) After sorting, centrifuge at 350 x g, 4°C for 10 min and resuspend in 1640 complete medium for later use.
[0061] 2. Transfection of miR-378a-5p mimics and inhibitor:
[0062] (1) First, miR-378a-5p mimics, miR-378a-5p inhibitor and negative control were dissolved according to the instructions to form a storage solution with a concentration of 20 μM;
[0063] (2) Then discard the Anti-CD3 coated in the 24-well plate the day before and sort the initial CD4 + T cells were plated into well plates (400 μL / well);
[0064] (3) Calculate the concentration of the transfection mimic and prepare the transfection system according to the following Tables 1 and 2:
[0065] Table 1 Transfection system of miR-378a-5p mimics
[0066]
[0067] Table 2 Transfection of miR-378a-5p inhibitor
[0068]
[0069] (4) After preparing the transfection system, flick the mixture with your fingers to mix well, let it stand at room temperature for 8 min, then add it dropwise to the corresponding well plate according to the grouping, and place it in a 37°C, 5% CO2 incubator for culture;
[0070] (5) After 6 hours of culture, add the initial CD4 + The cytokines that differentiate T lymphocytes into Th1 and Th2 are shown in Tables 3 and 4:
[0071] Table 3 Th1 polarization factors
[0072]
[0073] Table 4 Th2 polarization factors
[0074]
[0075] (6) Continue culturing for 48 h and harvest the cells for subsequent experiments.
[0076] 3. Transfection of siRNA-BRAF and OE-BRAF:
[0077] The target genes of miR-378a-5p were predicted by bioinformatics websites, and the dual luciferase reporter gene confirmed that its target gene was BRAF. The target genes of miR-378a-5p were predicted by TargetScan, miRWalk, and miRDB. The dual luciferase reporter analysis showed that the wild-type 3′UTR region of BRAF was regulated by miR-378a-5p, while the mutant type was not.
[0078] The target gene BRAF interference fragments were synthesized, namely: siRNA-BRAF-972, siRNA-BRAF-1341 and siRNA-BRAF-1845 / siRNA-NC, and their interference efficiency was detected by qRT-PCR. siRNA was transfected into the spleen of mice to initialize CD4 + In T cells, qRT-PCR technology was used to finally screen out the siRNA-BRAF-1341 fragment with the best interference effect for subsequent experiments. The sequences of the synthesized interference fragments are as follows: siRNA-BRAF-972: Sense: 5′-CCAACUUGAUUUGCUGUUUTT-3′;
[0079] Anti-sense:5′-AAACAGCAAAUCAAGUUGGTT-3′;
[0080] siRNA-BRAF-1341: Sense:5′-CCAACUGAUGCGCUGUCUUTT-3′;
[0081] Anti-sense:5′-AAGACAGCGCAUCAGUUGGTT-3′;
[0082] siRNA-BRAF-1845: Sense:5′-GCCACAACUGGCAAUUGUUTT-3′;
[0083] Anti-sense:5′-AACAAUUGCCAGUUGUGGCTT-3′.
[0084] The above interference fragment and control fragment siRNA-NC were synthesized by Shanghai Jima Pharmaceutical Technology Co., Ltd.
[0085] Packaging of target gene BRAF overexpression lentivirus. First, download the CDS sequence of the BRAF gene from NCBI, and hand it over to Fenghui Bio to construct a BRAF overexpression plasmid, which is inserted into pLVX-EGFP-IRES-PURO, with an empty vector as a control. Then, after plasmid amplification and plasmid extraction, the recombinant plasmid lentivirus is packaged to obtain the BRAF overexpression lentivirus, and its transfection efficiency is verified by qRT-PCR.
[0086] Initial CD4 + T cells were transfected with siRNA-BRAF-1341 and OE-BRAF to study the effect of target gene BRAF on initialization of CD4 + Effects on T cell differentiation. The siRNA-BRAF transfection system is shown in Table 5.
[0087] Table 5 siRNA-BRAF transfection system:
[0088]
[0089] Transfection of OE-BRAF: Add 1.5 μL Lipo 3000 for every 100 μL virus, flick to mix, let stand for 10 min, then add to cells, culture for 6 h, add corresponding polarization factors, and continue to culture for 48 h for subsequent experiments.
[0090] 4. Implementation plan for total cell RNA extraction and qRT-PCR:
[0091] In the present invention, qRT-PCR detection of target genes and miRNAs is respectively carried out by Bioscience one step RT qPCR kit (Sybr Green) and miRNA qRT-PCR TB from Genema Kit.
[0092] The total RNA extraction procedure refers to the TRIZOL operating instructions of Thermofisher Company. The specific extraction steps are as follows:
[0093] (1) According to the calculation of 1×10 7 Add 1 mL of TRIZOL to the cells, blow with a pipette until the liquid is clear and there are no cell clumps, invert and mix about 10 times, and let stand at room temperature for 10 minutes;
[0094] (2) Add 200 μL of chloroform (1 / 5 of the total volume) in a dark environment, mix vigorously for 15 seconds, and let stand at room temperature for 5 minutes;
[0095] (3) Centrifuge at 12000 × g, 4°C, 15 min, and carefully pipette the upper aqueous phase (about 400-500 μL, be careful not to aspirate the middle layer) into a new 1.5 mL EP tube;
[0096] (4) Add an equal volume of isopropanol, mix thoroughly by pipetting, and let stand at room temperature for 10 min;
[0097] (5) Centrifuge at 4°C, 12,000 × g, 10 min, and discard the supernatant (RNA forms white gel-like particles at the bottom);
[0098] (6) Add 1 mL of pre-cooled 75% alcohol (freshly prepared for immediate use);
[0099] (7) Centrifuge at 4°C, 7500 × g, 5 min, discard the supernatant (leave a little at the bottom and remove the supernatant with a 10 μL pipette), and blow dry on a clean bench for 5 min;
[0100] (8) Add 20-30 μL of enzyme-free water, take 1 μL of RNA to test purity and content, and use the rest for reverse transcription.
[0101] The qRT-PCR operation was performed according to the instructions of the real-time fluorescence quantitative PCR reagent. The reaction system is shown in Table 6 and the reaction conditions are shown in Table 7.
[0102] Table 6 qRT-PCR reaction system
[0103]
[0104] Table 7 qRT-PCR reaction conditions:
[0105]
[0106] The experimental results used the comparative Ct value method to detect the content of sample genes or miRNAs. The specific calculation formula is as follows:
[0107] Relative gene expression = 2-{〈﹙Ct value of target gene in experimental group﹚-﹙Ct value of reference gene in experimental group﹚〉-〈﹙Ct value of target gene in control group﹚-﹙Ct value of reference gene in control group﹚〉}
[0108] Among them, the internal reference gene is GAPDH for gene detection and U6 for miRNA detection.
[0109] The results are as follows Figure 1 to Figure 5 As shown:
[0110] Depend on Figure 1 As shown in Figure A, different concentration gradients of miR-378a-5p mimics were transfected into the initial CD4 + After 48 h in T cells, the expression of miR-378a-5p increased, but when the transfection concentration reached 60 nM, the expression of miR-378a-5p no longer increased with the increase of concentration.
[0111] Depend on Figure 1 As shown in Figure B, different concentrations of miR-378a-5p inhibitor were transfected into the initial CD4 + After 48 hours in T cells, the expression of miR-378a-5p was reduced, and the reduction effect was significant at a concentration of 100nM, while the reduction effect was not significant at a concentration of 150nM, which was not statistically significant.
[0112] Figure 2 The results showed that the spleen of mice primed with CD4 T cells after transfection with 60 nM miR-378a-5p mimics or 100 nM miR-378a-5 inhibitor + The differentiation of T cells reflects the effect of miR-378a-5p on initialization of CD4 + Influence of T cell differentiation. Figure 2 It can be seen that transfection of 60nM miR-378a-5p mimics can promote the expression of IFN-γ and transcription factor T-bet, representative factors of Th1 cells (Figures A and B), and inhibit the expression of IL-4 and transcription factor GATA-3, representative factors of Th2 cells (Figures E and F); transfection of miR-126a-5p inhibitor can inhibit the expression of IFN-γ and transcription factor T-bet, representative factors of Th1 cells (Figures C and D), and promote the expression of IL-4 and transcription factor GATA-3, representative factors of Th2 cells (Figures G and H).
[0113] Figure 3 Figure 1 shows the interference effects of different interference fragments siRNA-BRAF-972, siRNA-BRAF-1341, siRNA-BRAF-1845 / siRNA-NC and OE-BRAF. As shown in Figure B, the interference effect of the siRNA-BRAF-1341 fragment is the best.
[0114] Figure 4 The spleen of mice transfected with OE-BRAF and siRNA-BRAF-1341 primed CD4 + Differentiation of T cells. Figure 4 It can be seen that after transfection with siRNA-BRAF-1341, the mRNA levels of Th1 type cytokine IFN-γ and transcription factor T-bet significantly increased (Figure C and Figure D), while the mRNA levels of Th2 type cytokine IL-4 and transcription factor GATA-3 significantly decreased (Figure G and Figure H). After transfection with OE-BRAF, the mRNA levels of Th1 type cytokine IFN-γ and transcription factor T-bet significantly decreased (Figure A and Figure B), while the mRNA levels of Th2 type cytokine IL-4 and transcription factor GATA-3 significantly increased (Figure E and Figure F).
[0115] Figure 5 The results are as follows: The results show that the function of miR-378a-5p target gene BRAF was restored. Figure 5 It can be seen that in the mouse spleen, CD4 + After co-transfection of miR-378a-5p and BRAF in T cells, miR-378a-5p promoted the activation of CD4 + T cell differentiation towards Th1 can be restored by BRAF.
[0116] 5. Western blot
[0117] (1) Prepare SDS-PAGE gel according to Table 8.
[0118] Table 8 SDS-PAGE gel components
[0119]
[0120] (2) Electrophoresis: Add samples in the order of marker, sample 1, sample 2, ..., marker, and set the voltage to 80 V. When bromophenol blue runs to about 1 cm below the separation gel, adjust the voltage to 120 V and continue electrophoresis for about 2 h. When bromophenol blue runs to the bottom of the glass plate, stop electrophoresis.
[0121] (3) Transfer: First, activate the PVDF membrane in methanol for about 8-10 minutes, then soak the transfer clips, filter paper, etc. in pre-cooled transfer solution, peel off the SDS-PAGE gel, clamp the transfer clips in the order of red plate, sponge pad, filter paper, PVDF membrane, gel, filter paper, sponge pad, and black plate, place them in the transfer tank, turn on the electrophoresis instrument power, set the constant current to 250mA, and start transfer for 2h;
[0122] (4) Blocking: Prepare 5% skim milk and place on a shaker at room temperature, 65 rpm / min, for 2 hours;
[0123] (5) Washing the membrane: Wash the membrane with TBST at 110 rpm / min for 6 min each time, repeat three times;
[0124] (6) Primary antibody incubation: Prepare the antibody in advance, place the PVDF membrane in the prepared antibody, and incubate overnight at 4°C on a shaker;
[0125] (7) Washing the membrane: Recover the primary antibody and wash the membrane three times with TBST, each time for 6 min;
[0126] (8) Secondary antibody incubation: Prepare the secondary antibody in advance, place the PVDF membrane in the prepared antibody, and incubate on a shaker at room temperature for 2 h;
[0127] (9) Washing: Recover the secondary antibody and wash the membrane three times with TBST, each time for 6 min;
[0128] (10) Exposure: Prepare ECL chemiluminescent solution, take photos using an imaging system, save the results, and analyze the data.
[0129] The results are as follows Figure 6 , Figure 7 As shown:
[0130] Depend on Figure 6 It can be seen that transfection of miR-378a-5p mimics can promote the expression of IFN-γ, a representative factor of Th1 cells, and inhibit the expression of IL-4, a representative factor of Th2 cells; transfection of miR-378a-5p inhibitor can inhibit the expression of IFN-γ, a representative factor of Th1 cells, and promote the expression of IL-4, a representative factor of Th2 cells.
[0131] Depend on Figure 7 It can be seen that after transfection with siRNA-BRAF-1341, the expression of Th1 cytokine IFN-γ protein increased significantly, while the Th2 cytokine IL-4 decreased significantly. After transfection with OE-BRAF, the expression of Th1 cytokine IFN-γ protein decreased significantly, while the Th2 cytokine IL-4 increased significantly. The above findings indicate that BRAF inhibits the initial CD4 +T cells differentiate into Th1 and promote their differentiation into Th2.
[0132] 6. Flow cytometry
[0133] (1) Add 1 μL (24-well plate) of cell stimulation cocktail and protein transport inhibitor (500×) 5 h before harvesting cells;
[0134] (2) Adjust the cell volume per tube to 1×10 6 , resuspend with buffer 2;
[0135] (3) Surface staining: add 2 μL of PerCP-Cy5.5-CD3 and APC-CD4, vortex to mix, and incubate at 4°C in the dark for 30 min;
[0136] (4) Washing: add 1 mL of buffer 2 to each tube, centrifuge at 350 x g, 4°C for 8 min;
[0137] (5) Fixation: Add 600 μL of 4% paraformaldehyde to each tube and fix at room temperature in the dark for 15 min;
[0138] (6) Washing: add 1 mL of buffer 2 to each tube, centrifuge at 350 x g, 4°C for 8 min;
[0139] (7) Membrane disruption: Add 1 mL of buffer 3 to each tube and incubate at 4°C in the dark overnight to disrupt the membrane;
[0140] (8) Intracellular staining: The next day, centrifuge at 350 × g, 4°C for 8 min, add 100 μL of buffer 3 to each tube for resuspending, add 2 μL of PE-IFN-γ or PE-IL-4, and incubate at 4°C in the dark for 30 min;
[0141] (9) Washing: add 1 mL of buffer 2 to each tube, centrifuge at 350 x g, 4°C for 8 min;
[0142] (10) Loading the sample: Resuspend the sample in about 350 μL of buffer 2, filter it, and load it onto the machine.
[0143] The results are as follows Figure 8 to Figure 10 As shown:
[0144] Depend on Figure 8It can be seen that transfection of miR-378a-5p mimics can promote the expression of IFN-γ, a representative factor of Th1 cells, and inhibit the expression of IL-4, a representative factor of Th2 cells; transfection of miR-378a-5p inhibitor can inhibit the expression of IFN-γ, a representative factor of Th1 cells, and promote the expression of IL-4, a representative factor of Th2 cells.
[0145] Depend on Fig. 9 It can be seen that after transfection with siRNA-BRAF-1341, the expression of Th1 cytokine IFN-γ protein increased significantly, while the Th2 cytokine IL-4 decreased significantly. After transfection with OE-BRAF, the expression of Th1 cytokine IFN-γ protein decreased significantly, while the Th2 cytokine IL-4 increased significantly. The above findings also indicate that BRAF inhibits the initial CD4 + T cells differentiate into Th1 and promote their differentiation into Th2.
[0146] Fig.10 It is the result of the functional restoration of the miR-378a-5p target gene BRAF. Fig.10 It can be seen that in the mouse spleen, CD4 + After co-transfection of miR-378a-5p and BRAF in T cells, miR-378a-5p promoted the activation of CD4 + T cell differentiation towards Th1 can be restored by BRAF.
[0147] Example 2
[0148] In this example, the targeting relationship between miR-378a-5p and BRAF was detected by dual luciferase reporter gene.
[0149] Referring to the Dual-Luciferase Reporter Assay System kit of Promega, the specific steps are as follows:
[0150] (1) Prepare 293T cells and target plasmids for transfection in 96-well plates in advance, and wait until the cell density reaches 50%-70%.
[0151] (2) 10 μL DMEM was thoroughly mixed with 0.16 μg of Dlk1-3UTR target plasmid and 5 pmol of mmu-miR-378a-5p / NC and placed at room temperature (solution A). Then, 10 μL DMEM was thoroughly mixed with 0.3 μL of transfection reagent (concentration of 0.8 mg / ml) (solution B) and placed at room temperature for 5 min.
[0152] (3) Mix solution A and solution B thoroughly and leave at room temperature for 20 min.
[0153] (4) Before transfection, replace the culture medium with fresh one, then add the transfection mixture and mix well. Incubate at 37°C and 5% CO2.
[0154] (5) Replace the culture medium with fresh medium 6 hours after transfection and collect cells for testing 48 hours after transfection.
[0155] (6) The ratio of the expression levels of Renilla luciferase to firefly luciferase is the relative activity of Renilla luciferase, which is the activity of the corresponding target gene (three replicates).
[0156] Experimental results:
[0157] The BRAF wild-type (wt) 3′UTR and the 3′UTR with sequence mutations containing the predicted binding site were constructed into psiCHECK-2, and dual luciferase reporter assay revealed that the BRAF wild-type 3′UTR region was regulated by miR-378a-5p, while the mutant type was not. Fig.11 shown.
[0158] Example 3
[0159] This example verifies the expression of miR-378a-5p and BRAF after mice were immunized with rEg.P29.
[0160] (1) Expression and purification of rEg.P29: The recombinant strain previously stored in our laboratory was selected, induced and expanded for culture, and then purified using affinity chromatography.
[0161] (2) Experimental animal grouping, immunization and sampling: 18 female Balb / c mice aged 6-8 weeks were randomly divided into three groups (6 mice in each group), namely PBS group, adjuvant group and rEg.P29+adjuvant group. The immunization scheme was as follows: PBS group (100μL PBS), adjuvant group (50μL PBS+50μL adjuvant), rEg.P29+adjuvant group (20μgrEg.P29+50μL PBS+50ML FCA). Immunization was performed twice, with an interval of 1 week. Both immunizations were performed by subcutaneous three-point injection in the abdomen. The adjuvant used for the first immunization was Freund's complete adjuvant, and the adjuvant used for the second immunization was Freund's incomplete adjuvant. One week after the second immunization, spleen CD4 + T cells, RNA and protein extraction.
[0162] (3) The RNA expression of miR-378a-5p and BRAF was detected by qRT-PCR, and the protein expression of BRAF was detected by Western blot. Fig.12As shown, compared with the PBS and adjuvant groups, the expression of miR-378a-5p in the P29+adjuvant group was significantly increased, and the expression level of BRAF was significantly decreased.
[0163] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. miR-378a-5p promotes the initialization of CD4 + Application in the differentiation of T cells into Th1 direction.
2. The use according to claim 1, characterized in that: The nucleotide sequence of miR-378a-5p is CUCCUGACUCCAGGUCCUGUGU.
3. Application of miR-378a-5p mimics in the preparation of drugs for the prevention or treatment of echinococcosis.
4. The use according to claim 3, characterized in that: The miR-378a-5p mimic is double-stranded: the sense strand sequence is: CUCCUGACUCCAGGUCCUGUGU, and the antisense strand sequence is: ACAGGACCUGGAGUCAGGAGUU.
5. A drug for preventing echinococcosis, characterized in that: Its active ingredients include miR-378a-5p mimics.
6. The drug according to claim 5, characterized in that The miR-378a-5p mimic is double-stranded: the sense strand sequence is: CUCCUGACUCCAGGUCCUGUGU, and the antisense strand sequence is: ACAGGACCUGGAGUCAGGAGUU.
7. The drug according to claim 5 or 6, characterized in that The dosage form of the drug is injection.
8. A drug for treating echinococcosis, characterized in that: Its active ingredients include miR-378a-5p mimics.
9. The drug according to claim 8, characterized in that The miR-378a-5p mimic is double-stranded: the sense strand sequence is: CUCCUGACUCCAGGUCCUGUGU, and the antisense strand sequence is: ACAGGACCUGGAGUCAGGAGUU.
10. The drug according to claim 8 or 9, characterized in that The dosage form of the drug is injection.
